Currently, in the adult population, there are three anti-CD19 CAR-T cell products available for the treatment of various non-Hodgkin’s lymphomas, one product for acute lymphoblastic leukaemia and two anti-B-cell maturation antigen (BCMA) CAR-T cell products for treatment of multiple myeloma. Here, TNFRSF17 is linked to non-Hodgkin lymphoma.